USFDA concludes inspection at Glenmark Pharmaceuticals’ Aurangabad facility with one observation

02 Jul 2022 Evaluate

The United States Food and Drug Administration (USFDA) has issued Form 483 with one observation after an inspection at Glenmark Pharmaceuticals’ formulation manufacturing facility based out of Aurangabad, India between June 27, 2022 and July 1, 2022. 

The company is committed to undertake all necessary steps required to address their observation at the earliest. The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2001.05 30.30 (1.54%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×